Table 2. Clinical findings at transplant of patients undergoing allogeneic unrelated transplant.
| Patients, N | 121 |
| Median age, years (range) | 49 (17–65) |
| Sex M/F (%) | 69/52 (57/43) |
| Diagnosis | |
| ALL | 2 |
| AML | 25 |
| CML | 3 |
| MDS | 5 |
| MMF | 6 |
| NHL | 28 |
| B-CLL | 9 |
| HD | 41 |
| MF/SS | 2 |
| Conditioning regimens (%) | |
| TBI+Alem+Flud+Melph | 50 (41) |
| Thiotepa+Cyclophamide+ATG | 71 (59) |
| Source of stem cell (%) | |
| BM | 54 (45) |
| PB | 67 (55) |
| Disease status at transplant (%) | |
| Standard phase | 41 (34) |
| High-risk phase | 80 (66) |
| Years of follow up, median (range) | 2.43 (0.35–8.36) |
Abbreviations: Alem, alemtuzumab; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; B-CLL, B-cell chronic lymphocytic leukemia; BM, bone marrow; CML, chronic myeloid leukemia; F, female; Flud, fludarabine; HD, Hodgkin's disease; M, male; MDS, myelodysplastic Syndrome; Melph, melphalan; MF, mycosis fungoides; MMF, myelofibrosis; NHL, non-Hodgkin's lymphoma; PB, peripheral blood; SS, Sezary's syndrome; TBI, total body irradiation.